Daniel Mikol

Daniel Mikol

Company: Global Neuroscience Development Amgen

Job title: Executive Medical Director

Bio:

Neuroscience Development lead: early/late stage migraine, pipeline products. Development lead for Erenumab (Aimovig) for migraine prevention.

Seminars:

Keynote: Migraine; From Hysteria to Neurobiological Entity 8:40 am

Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more

day: Day One

Workshop A 9:00 am - 10:00 am

Working with Migraine Patient Advocacy Organizations on Clinical Trial Design and Recruitment The patient advocacy perspective is one that is commonly discussed amongst migraine stakeholders, getting the insight from those who work to ensure the migraine awareness is widespread and the outreach to patients is great.Read more

Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 12:00 am - 2:00 pm

Read more

day: Day Two

Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 9:00 am

Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more

day: Day One

Discussing the Current Anti-CGRP Status & the Challenges & Opportunities They Pose 9:00 am

Understand pathophysiology data from imaging studies Summarize new guidelines on developing Acute Treatment for Migraine Assess treatment gaps in Preventive treatment of Migraine and the unmet patient needRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.